Nasdaq
$0.5240▼ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $761,546.49Shares out 1.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 2d agoAfter-hours26.10.23 05:054Ownership#●●●
Nexentis Technologies Inc.
Insider Itzhaik Asaf of Nexentis Technologies Inc. filed a Form 4 to report changes in beneficial ownership of securities as of October 15, 2026. This filing formalizes the update regarding the insider's equity holdings.…more
$0.5240-0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoRegular26.10.20 22:36PRE 14AOther
Nexentis Technologies Inc.
Nexentis Technologies will hold its annual meeting on December 14, 2026, to vote on director re-elections, the issuance of securities at a 20% discount, auditor appointment, and a convertible note financing facility of up to $10 million. As of October 19, 2026, the company has 2,962,073 shares of common stock outstanding.…more
$0.5240-0.04%vs prev closeView filingShare - 5d agoAfter-hours26.10.20 05:058-KKey event
Nexentis Technologies Inc.
On October 15, 2026, Nexentis Technologies Inc. issued a total of 922,188 shares of common stock to its executives, directors, and consultants. These shares were issued as compensation under the 2022 Share Incentive Plan and for various consulting services, relying on the registration exemption under Section 4(a)(2) of the Securities Act.…more
$0.5240-0.04%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 21:07#●●●#●●●
Nexentis Subsidiary MitoCareX Expands Bioinformatics Capabilities
Nexentis subsidiary MitoCareX is enhancing its bioinformatics capabilities to improve disease-pathway analysis within its computational drug-discovery platform. This initiative focuses on research development and does not represent immediate financial or operational results.…more
$0.5240-0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Pre-market26.10.07 20:32
●●●●●●●● ●●●●● ●●●●●●
Nexentis' subsidiary, MitoCareX Bio, has deployed its computational drug discovery infrastructure on Google Cloud Platform to enhance operational flexibility and data governance. This infrastructure migration is a strategic technical update and does not represent a material financial event.…more
$0.5240-0.04%vs prev close - 9.24Pre-market26.09.24 20:50
●●●●●●●● ●●●●● ●●●●●●
Nexentis subsidiary MitoCareX has appointed computational chemistry expert Prof. Dan T. Major to its Scientific Advisory Board. The appointment aims to strengthen the company's internal computational capabilities for drug discovery.…more
$0.5240-0.04%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report